Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins

Yohei Doi, Jun Ichi Wachino, Masaji Ishiguro, Hiroshi Kurokawa, Kunikazu Yamane, Naohiro Shibata, Keigo Shibayama, Keiko Yokoyama, Haru Kato, Tetsuya Yagi, Yoshichika Arakawa

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Escherichia coli HKY28, a ceftazidime-resistant strain isolated from a urine specimen in Japan, produced an inhibitor-sensitive AmpC β-lactamase variant. The deduced amino acid sequence of the enzyme contained a number of substitutions and a tripeptide deletion (Gly286-Ser287-Asp288) compared with the sequence of native AmpC of E. coli. When the deletion was reverted by a 9-base insertion at the relevant site of ampC in the clone, the typical inhibitor-resistant phenotype of AmpC was restored, while at the same time the levels of resistance to ceftazidime, cefpirome, and cefepime were reduced eightfold or more. Molecular modeling studies indicated that a structural change took place in the H-10 helix as a result of the deletion, and this change caused an alteration of the substrate binding site, leading to a unique phenotype analogous to that of inhibitor-sensitive class A extended-spectrum β-lactamases. The degree of inhibition was greater with sulbactam and tazobactam than with clavulanic acid. To our knowledge, this is the first report to have characterized an E. coli ampC that encodes chromosomal AmpC β-lactamase sensitive to the available β-lactamase inhibitors.

Original languageEnglish
Pages (from-to)2652-2658
Number of pages7
JournalAntimicrobial agents and chemotherapy
Volume48
Issue number7
DOIs
Publication statusPublished - 01-07-2004

Fingerprint

Cephamycins
Ceftazidime
cefpirome
Escherichia coli
Phenotype
Sulbactam
Clavulanic Acid
Amino Acid Sequence
Japan
Clone Cells
Binding Sites
Urine
Enzymes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Doi, Yohei ; Wachino, Jun Ichi ; Ishiguro, Masaji ; Kurokawa, Hiroshi ; Yamane, Kunikazu ; Shibata, Naohiro ; Shibayama, Keigo ; Yokoyama, Keiko ; Kato, Haru ; Yagi, Tetsuya ; Arakawa, Yoshichika. / Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. In: Antimicrobial agents and chemotherapy. 2004 ; Vol. 48, No. 7. pp. 2652-2658.
@article{45dd9809629f473e8ce56548f9b9d786,
title = "Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins",
abstract = "Escherichia coli HKY28, a ceftazidime-resistant strain isolated from a urine specimen in Japan, produced an inhibitor-sensitive AmpC β-lactamase variant. The deduced amino acid sequence of the enzyme contained a number of substitutions and a tripeptide deletion (Gly286-Ser287-Asp288) compared with the sequence of native AmpC of E. coli. When the deletion was reverted by a 9-base insertion at the relevant site of ampC in the clone, the typical inhibitor-resistant phenotype of AmpC was restored, while at the same time the levels of resistance to ceftazidime, cefpirome, and cefepime were reduced eightfold or more. Molecular modeling studies indicated that a structural change took place in the H-10 helix as a result of the deletion, and this change caused an alteration of the substrate binding site, leading to a unique phenotype analogous to that of inhibitor-sensitive class A extended-spectrum β-lactamases. The degree of inhibition was greater with sulbactam and tazobactam than with clavulanic acid. To our knowledge, this is the first report to have characterized an E. coli ampC that encodes chromosomal AmpC β-lactamase sensitive to the available β-lactamase inhibitors.",
author = "Yohei Doi and Wachino, {Jun Ichi} and Masaji Ishiguro and Hiroshi Kurokawa and Kunikazu Yamane and Naohiro Shibata and Keigo Shibayama and Keiko Yokoyama and Haru Kato and Tetsuya Yagi and Yoshichika Arakawa",
year = "2004",
month = "7",
day = "1",
doi = "10.1128/AAC.48.7.2652-2658.2004",
language = "English",
volume = "48",
pages = "2652--2658",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

Doi, Y, Wachino, JI, Ishiguro, M, Kurokawa, H, Yamane, K, Shibata, N, Shibayama, K, Yokoyama, K, Kato, H, Yagi, T & Arakawa, Y 2004, 'Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins', Antimicrobial agents and chemotherapy, vol. 48, no. 7, pp. 2652-2658. https://doi.org/10.1128/AAC.48.7.2652-2658.2004

Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. / Doi, Yohei; Wachino, Jun Ichi; Ishiguro, Masaji; Kurokawa, Hiroshi; Yamane, Kunikazu; Shibata, Naohiro; Shibayama, Keigo; Yokoyama, Keiko; Kato, Haru; Yagi, Tetsuya; Arakawa, Yoshichika.

In: Antimicrobial agents and chemotherapy, Vol. 48, No. 7, 01.07.2004, p. 2652-2658.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins

AU - Doi, Yohei

AU - Wachino, Jun Ichi

AU - Ishiguro, Masaji

AU - Kurokawa, Hiroshi

AU - Yamane, Kunikazu

AU - Shibata, Naohiro

AU - Shibayama, Keigo

AU - Yokoyama, Keiko

AU - Kato, Haru

AU - Yagi, Tetsuya

AU - Arakawa, Yoshichika

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Escherichia coli HKY28, a ceftazidime-resistant strain isolated from a urine specimen in Japan, produced an inhibitor-sensitive AmpC β-lactamase variant. The deduced amino acid sequence of the enzyme contained a number of substitutions and a tripeptide deletion (Gly286-Ser287-Asp288) compared with the sequence of native AmpC of E. coli. When the deletion was reverted by a 9-base insertion at the relevant site of ampC in the clone, the typical inhibitor-resistant phenotype of AmpC was restored, while at the same time the levels of resistance to ceftazidime, cefpirome, and cefepime were reduced eightfold or more. Molecular modeling studies indicated that a structural change took place in the H-10 helix as a result of the deletion, and this change caused an alteration of the substrate binding site, leading to a unique phenotype analogous to that of inhibitor-sensitive class A extended-spectrum β-lactamases. The degree of inhibition was greater with sulbactam and tazobactam than with clavulanic acid. To our knowledge, this is the first report to have characterized an E. coli ampC that encodes chromosomal AmpC β-lactamase sensitive to the available β-lactamase inhibitors.

AB - Escherichia coli HKY28, a ceftazidime-resistant strain isolated from a urine specimen in Japan, produced an inhibitor-sensitive AmpC β-lactamase variant. The deduced amino acid sequence of the enzyme contained a number of substitutions and a tripeptide deletion (Gly286-Ser287-Asp288) compared with the sequence of native AmpC of E. coli. When the deletion was reverted by a 9-base insertion at the relevant site of ampC in the clone, the typical inhibitor-resistant phenotype of AmpC was restored, while at the same time the levels of resistance to ceftazidime, cefpirome, and cefepime were reduced eightfold or more. Molecular modeling studies indicated that a structural change took place in the H-10 helix as a result of the deletion, and this change caused an alteration of the substrate binding site, leading to a unique phenotype analogous to that of inhibitor-sensitive class A extended-spectrum β-lactamases. The degree of inhibition was greater with sulbactam and tazobactam than with clavulanic acid. To our knowledge, this is the first report to have characterized an E. coli ampC that encodes chromosomal AmpC β-lactamase sensitive to the available β-lactamase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=3042677882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042677882&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.7.2652-2658.2004

DO - 10.1128/AAC.48.7.2652-2658.2004

M3 - Article

VL - 48

SP - 2652

EP - 2658

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -